Outcome of patients treated with molecular adsorbent recirculating system albumin dialysis: A national multicenter study

被引:8
作者
Camus, Christophe [1 ]
Locher, Clara [2 ]
Saliba, Faouzi [3 ]
Goubaux, Bernard [4 ]
Bonadona, Agnes [5 ]
Lavayssiere, Laurence [6 ]
Paugam, Catherine [7 ]
Quinart, Alice [8 ]
Barbot, Olivier [9 ]
Dharancy, Sebastien [10 ]
Delafosse, Bertrand [11 ]
Pichon, Nicolas [12 ]
Barraud, Helene [13 ]
Galbois, Arnaud [14 ]
Veber, Benoit [15 ]
Cayot, Sophie [16 ]
Souche, Bruno [17 ]
机构
[1] Hop Pontchaillou, Serv Reanimat Med, Rennes, France
[2] Ctr Invest Clin INSERM 1414, Lab Pharmacol, Rennes, France
[3] Hop Paul Brousse, AP HP, Ctr Hepatobiliaire, Villejuif, France
[4] Hop Archet II, Serv Anesthesie Reanimat, Nice, France
[5] Hop La Tronche, Serv Reanimat Med, Grenoble, France
[6] Hop Rangueil Larrey, Serv Nephrol, Toulouse, France
[7] Hop Beaujon, Serv Anesthesie Reanimat Chirurg, Clichy, France
[8] Hop Pellegrin, Serv Anesthesie Reanimat, Bordeaux, France
[9] Hop Jean Minjoz, Serv Reanimat Med, Besancon, France
[10] Hop Claude Huriez, Serv Hepatol, Lille, France
[11] Hop Edouard Herriot, Serv Anesthesie Reanimat Chirurg, Lyon, France
[12] Hop Dupuytren, Serv Reanimat Med, Limoges, France
[13] Hop Brabois, Serv Hepatogastroenterol, Vandoeuvre Les Nancy, France
[14] Hop St Antoine, Serv Reanimat Med, Paris, France
[15] Hop Charles Nicolle, Serv Reanimat Chirurg, Rouen, France
[16] CHU Estaing, Serv Reanimat, Clermont Ferrand, France
[17] Hop St Eloi, Serv Anesthesie Reanimat, Montpellier, France
关键词
liver transplantation; MARS albumin dialysis; outcome; retrospective study; CHRONIC LIVER-FAILURE; HEPATIC-ENCEPHALOPATHY; TRANSPLANTATION; SURVIVAL; INJURY; MARS;
D O I
10.1002/jgh3.12359
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim The molecular adsorbent recirculating system (MARS) is the most widely used device to treat liver failure. Nevertheless, data from widespread real-life use are lacking. Methods This was a retrospective multicenter study conducted in all French adult care centers that used MARS between 2004 and 2009. The primary objective was to evaluate patient survival according to the liver disease and listing status. Factors associated with mortality were the secondary objectives. Results A total of 383 patients underwent 393 MARS treatments. The main indications were acute liver failure (ALF, 32.6%), and severe cholestasis (total bilirubin >340 mu mol/L) (37.2%), hepatic encephalopathy (23.7%), and/or acute kidney injury-hepatorenal syndrome (22.9%) most often among patients with chronic liver disease. At the time of treatment, 34.4% of the patients were listed. Overall, the hospital survival rate was 49% (95% CI: 44-54%) and ranged from 25% to 81% depending on the diagnosis of the liver disease. In listed patients versus those not listed, the 1-year survival rate was markedly better in the setting of nonbiliary cirrhosis (59% vs 15%), early graft nonfunction (80% vs 0%), and late graft dysfunction (72% vs 0%) (all P < 0.001). Among nonbiliary cirrhotic patients, hospital mortality was associated with the severity of liver disease (HE and severe cholestasis) and not being listed for transplant. In ALF, paracetamol etiology and >= 3 MARS sessions were associated with better transplant-free survival. Conclusion Our study suggests that MARS should be mainly used as a bridge to liver transplantation. Survival was correlated with being listed for most etiologies and with the intensity of treatment in ALF.
引用
收藏
页码:757 / 763
页数:7
相关论文
共 26 条
[1]   2018 Annual Report of the European Liver Transplant Registry (ELTR)-50-year evolution of liver transplantation [J].
Adam, Rene ;
Karam, Vincent ;
Cailliez, Valerie ;
Grady, John G. O. ;
Mirza, Darius ;
Cherqui, Daniel ;
Klempnauer, Jurgen ;
Salizzoni, Mauro ;
Pratschke, Johann ;
Jamieson, Neville ;
Hidalgo, Ernest ;
Paul, Andreas ;
Lopez Andujar, Rafael ;
Lerut, Jan ;
Fisher, Lutz ;
Boudjema, Karim ;
Fondevila, Constantino ;
Soubrane, Olivier ;
Bachellier, Philippe ;
Pinna, Antonio D. ;
Berlakovich, Gabriela ;
Bennet, William ;
Pinzani, Massimo ;
Schemmer, Peter ;
Zieniewicz, Krzysztof ;
Jimenez Romero, Carlos ;
De Simone, Paolo ;
Ericzon, Bo-Goran ;
Schneeberger, Stefan ;
Wigmore, Stephen J. ;
Fabregat Prous, Joan ;
Colledan, Michele ;
Porte, Robert J. ;
Yilmaz, Sezai ;
Azoulay, Daniel ;
Pirenne, Jacques ;
Line, Pal-Dag ;
Trunecka, Pavel ;
Navarro, Francis ;
Valdivieso Lopez, Andres ;
De Carlis, Luciano ;
Rufian Pena, Sebastian ;
Kochs, Eberhard ;
Duvoux, Christophe .
TRANSPLANT INTERNATIONAL, 2018, 31 (12) :1293-1317
[2]   Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial [J].
Banares, Rafael ;
Nevens, Frederik ;
Larsen, Fin Stolze ;
Jalan, Rajiv ;
Albillos, Agustin ;
Dollinger, Matthias ;
Saliba, Faouzi ;
Sauerbruch, Tilman ;
Klammt, Sebastian ;
Ockenga, Johann ;
Pares, Albert ;
Wendon, Julia ;
Bruennler, Tanja ;
Kramer, Ludwig ;
Mathurin, Philippe ;
de la Mata, Manuel ;
Gasbarrini, Antonio ;
Muellhaupt, Beat ;
Wilmer, Alexander ;
Laleman, Wim ;
Eefsen, Martin ;
Sen, Sambit ;
Zipprich, Alexander ;
Tenorio, Teresa ;
Pavesi, Marco ;
Schmidt, Hartmut H. -J. ;
Mitzner, Steffen ;
Williams, Roger ;
Arroyo, Vicente .
HEPATOLOGY, 2013, 57 (03) :1153-1162
[3]   The burden of liver disease in Europe: A review of available epidemiological data [J].
Blachier, Martin ;
Leleu, Henri ;
Peck-Radosavljevic, Markus ;
Valla, Dominique-Charles ;
Roudot-Thoraval, Francoise .
JOURNAL OF HEPATOLOGY, 2013, 58 (03) :593-608
[4]   Liver Transplantation Avoided in Patients With Fulminant Hepatic Failure Who Received Albumin Dialysis With the Molecular Adsorbent Recirculating System While on the Waiting List: Impact of the Duration of Therapy [J].
Camus, Christophe ;
Lavoue, Sylvain ;
Gacouin, Arnaud ;
Compagnon, Philippe ;
Boudjema, Karim ;
Jacquelinet, Christian ;
Thomas, Remi ;
Le Tulzo, Yves .
THERAPEUTIC APHERESIS AND DIALYSIS, 2009, 13 (06) :549-555
[5]   Molecular adsorbent recirculating system treatment for patients with liver failure: the Hong Kong experience [J].
Chiu, Alexander ;
Chan, Lina Mun Yee ;
Fan, Sheung Tat .
LIVER INTERNATIONAL, 2006, 26 (06) :695-702
[6]   Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF) [J].
Cordoba, Juan ;
Ventura-Cots, Meritxell ;
Simon-Talero, Macarena ;
Amoros, Alex ;
Pavesi, Marco ;
Vilstrup, Hendrik ;
Angeli, Paolo ;
Domenicali, Marco ;
Gines, Pere ;
Bernardi, Mauro ;
Arroyo, Vicente .
JOURNAL OF HEPATOLOGY, 2014, 60 (02) :275-281
[7]   Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis [J].
Hassanein, Tarek I. ;
Tofteng, Flemming ;
Brown, Robert S., Jr. ;
McGuire, Brendan ;
Lynch, Patrick ;
Mehta, Ravindra ;
Larsen, Fin S. ;
Gornbein, Jeff ;
Stange, Jan ;
Blei, Andres T. .
HEPATOLOGY, 2007, 46 (06) :1853-1862
[8]  
He GL, 2015, INT J CLIN EXP MED, V8, P17046
[9]   Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study [J].
Heemann, U ;
Treichel, U ;
Loock, J ;
Philipp, T ;
Gerken, G ;
Malago, M ;
Klammt, S ;
Loehr, M ;
Liebe, S ;
Mitzner, S ;
Schmidt, R ;
Stange, J .
HEPATOLOGY, 2002, 36 (04) :949-958
[10]   Molecular adsorbent recirculating system in patients with early allograft dysfunction after liver transplantation: A pilot study [J].
Hetz, Hubert ;
Faybik, Peter ;
Berlakovich, Gabriela ;
Baker, Amir ;
Bacher, Andreas ;
Burghuber, Christopher ;
Sandner, Sigrid E. ;
Steltzer, Heinz ;
Krenn, Claus Georg .
LIVER TRANSPLANTATION, 2006, 12 (09) :1357-1364